Literature DB >> 10408726

Exclusion of HIV coreceptors CXCR4, CCR5, and CCR3 from the HIV envelope.

L B Lallos1, S Laal, J A Hoxie, S Zolla-Pazner, J C Bandres.   

Abstract

Both HIV-1 primary isolates and laboratory strains incorporate cell-derived molecules into their envelopes depending on the host cell in which they are grown. This incorporation is not random and, specifically, HIV-1 has been shown to select against the incorporation into its surface of CD4, its main receptor. In this study, we have looked at the incorporation of HIV coreceptors CXCR4, CCR5, and CCR3 into the HIV envelope. For this purpose, we grew HIV-1 primary isolate BZ167 in several cell lines and PBMCs, and the envelope profiles of the resulting viruses were determined with a virus-binding ELISA. While the virus particle gained several molecules when passed through the different cell lines (e.g., ICAM-3, LFA-1, ICAM-1, or MHC class II), BZ167 never incorporated significant levels of CXCR4, CCR5, or CCR3 into its envelope even though some or all of the cell lines in which it was grown expressed them. These results show that HIV-1 selects against the incorporation of these chemokine receptors into its envelope molecule, as it does against the incorporation of CD4.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10408726     DOI: 10.1089/088922299310601

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  9 in total

Review 1.  Targeting CCR5 for anti-HIV research.

Authors:  W-G Gu; X-Q Chen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-06-11       Impact factor: 3.267

2.  Differential incorporation of CD45, CD80 (B7-1), CD86 (B7-2), and major histocompatibility complex class I and II molecules into human immunodeficiency virus type 1 virions and microvesicles: implications for viral pathogenesis and immune regulation.

Authors:  M T Esser; D R Graham; L V Coren; C M Trubey; J W Bess; L O Arthur; D E Ott; J D Lifson
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

3.  Expression of Nef downregulates CXCR4, the major coreceptor of human immunodeficiency virus, from the surfaces of target cells and thereby enhances resistance to superinfection.

Authors:  Stephanie Venzke; Nico Michel; Ina Allespach; Oliver T Fackler; Oliver T Keppler
Journal:  J Virol       Date:  2006-08-23       Impact factor: 5.103

4.  Distinct mechanisms of CD4+ and CD8+ T-cell activation and bystander apoptosis induced by human immunodeficiency virus type 1 virions.

Authors:  Geoffrey H Holm; Dana Gabuzda
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

5.  Antibody against integrin lymphocyte function-associated antigen 1 inhibits HIV type 1 infection in primary cells through caspase-8-mediated apoptosis.

Authors:  Tiffany N Walker; Lisa M Cimakasky; Ebony M Coleman; M Nia Madison; James E K Hildreth
Journal:  AIDS Res Hum Retroviruses       Date:  2012-08-20       Impact factor: 2.205

6.  Anti-HIV-1 activity of salivary MUC5B and MUC7 mucins from HIV patients with different CD4 counts.

Authors:  Habtom H Habte; Corena de Beer; Zoë E Lotz; Paul Roux; Anwar S Mall
Journal:  Virol J       Date:  2010-10-14       Impact factor: 4.099

7.  Passive and active inclusion of host proteins in human immunodeficiency virus type 1 gag particles during budding at the plasma membrane.

Authors:  Maria Hammarstedt; Henrik Garoff
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

8.  Targeted infection of HIV-1 Env expressing cells by HIV(CD4/CXCR4) vectors reveals a potential new rationale for HIV-1 mediated down-modulation of CD4.

Authors:  Zhiping Ye; George G Harmison; Jack A Ragheb; Manfred Schubert
Journal:  Retrovirology       Date:  2005-12-21       Impact factor: 4.602

9.  The inhibition of the Human Immunodeficiency Virus type 1 activity by crude and purified human pregnancy plug mucus and mucins in an inhibition assay.

Authors:  Habtom H Habte; Corena de Beer; Zoë E Lotz; Marilyn G Tyler; Leann Schoeman; Delawir Kahn; Anwar S Mall
Journal:  Virol J       Date:  2008-05-19       Impact factor: 4.099

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.